RxDoctor Payments Data

Cindy Montes

Family · Slippery Rock, PANPI 1417506767

Payments from drug & device makers

$5,315in general payments, 2019–2025

Across 204 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Axsome Therapeutics, Inc.$1K
  • Pfizer$517
  • Biohaven Pharmaceutical Holding Company Ltd.$364
  • Teva Pharmaceuticals USA, Inc.$291
  • Biohaven Pharmaceuticals, Inc.$265
  • plus $207 from 3 others

What the payments were for

  • Speaking & faculty fees$87516%
  • Food & beverage$4,35382%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,315 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$70,223
Medicare patients
58
Services billed
10,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant78$99,275
Nurtec OdtRimegepant Sulfate66$64,785
Emgality PenGalcanezumab-Gnlm63$55,167
QuliptaAtogepant31$33,073
Aimovig AutoinjectorErenumab-Aooe43$31,031
Ajovy AutoinjectorFremanezumab-Vfrm31$21,928
Prochlorperazine Maleate40$490
Topiramate80$484
Zonisamide42$453
Ondansetron OdtOndansetron12$213
Gabapentin39$206
Sumatriptan Succinate12$41
Propranolol Hcl13$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,506$132,348109 claims
PfizerNurtec Odt$517$64,78566 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Slippery Rock

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →